Tags

Type your tag names separated by a space and hit enter

Currently approved and emerging oral therapies in multiple sclerosis: An update for the ophthalmologist.
Surv Ophthalmol 2016 May-Jun; 61(3):318-32SO

Abstract

Although our understanding of multiple sclerosis (MS) has grown substantially, its cause remains unknown. Nonetheless, in the past 3 decades, there have been tremendous advancements in the development of disease-modifying drugs (DMDs). In July 1993, the United States Food and Drug Administration approved the first disease-modifying drug-interferon β- and there are currently 13 medications approved for use in relapsing MS. All the early medications are administered either as a subcutaneous or intramuscular injection, and despite the clinical efficacy and safety of these medications, many patients were hampered by the inconvenience of injections and injection-related side effects. In September 2010, the first oral DMD-fingolimod-was approved. Since then, 2 additional oral DMDs (teriflunomide and dimethyl fumarate) have been approved, and several other oral medications are being evaluated in extensive MS development programs. Because of frequent ocular involvement, ophthalmologists are often involved in the care of MS patients and therefore need to be aware of the current treatment regimens prescribed by neurologists, some of which can have significant ophthalmic adverse events. We update the current advancements in the treatment of MS and discuss the published clinical data on the efficacy and safety of the currently approved and emerging oral therapies in MS.

Authors+Show Affiliations

Department of Neurology, Duke University Medical Center, Durham, North Carolina, USA.Department of Neurology, Duke University Medical Center, Durham, North Carolina, USA; Department of Ophthalmology, Duke Eye Center, Durham, North Carolina, USA. Electronic address: tariq.bhatti@duke.edu.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

26703886

Citation

Eckstein, Christopher, and M Tariq Bhatti. "Currently Approved and Emerging Oral Therapies in Multiple Sclerosis: an Update for the Ophthalmologist." Survey of Ophthalmology, vol. 61, no. 3, 2016, pp. 318-32.
Eckstein C, Bhatti MT. Currently approved and emerging oral therapies in multiple sclerosis: An update for the ophthalmologist. Surv Ophthalmol. 2016;61(3):318-32.
Eckstein, C., & Bhatti, M. T. (2016). Currently approved and emerging oral therapies in multiple sclerosis: An update for the ophthalmologist. Survey of Ophthalmology, 61(3), pp. 318-32. doi:10.1016/j.survophthal.2015.12.001.
Eckstein C, Bhatti MT. Currently Approved and Emerging Oral Therapies in Multiple Sclerosis: an Update for the Ophthalmologist. Surv Ophthalmol. 2016;61(3):318-32. PubMed PMID: 26703886.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Currently approved and emerging oral therapies in multiple sclerosis: An update for the ophthalmologist. AU - Eckstein,Christopher, AU - Bhatti,M Tariq, Y1 - 2015/12/15/ PY - 2015/10/14/received PY - 2015/12/07/accepted PY - 2015/12/26/entrez PY - 2015/12/26/pubmed PY - 2016/10/1/medline KW - central nervous system KW - dimethyl fumarate KW - disability KW - disease-modifying drugs KW - fingolimod KW - magnetic resonance imaging KW - multiple sclerosis KW - relapses KW - teriflunomide SP - 318 EP - 32 JF - Survey of ophthalmology JO - Surv Ophthalmol VL - 61 IS - 3 N2 - Although our understanding of multiple sclerosis (MS) has grown substantially, its cause remains unknown. Nonetheless, in the past 3 decades, there have been tremendous advancements in the development of disease-modifying drugs (DMDs). In July 1993, the United States Food and Drug Administration approved the first disease-modifying drug-interferon β- and there are currently 13 medications approved for use in relapsing MS. All the early medications are administered either as a subcutaneous or intramuscular injection, and despite the clinical efficacy and safety of these medications, many patients were hampered by the inconvenience of injections and injection-related side effects. In September 2010, the first oral DMD-fingolimod-was approved. Since then, 2 additional oral DMDs (teriflunomide and dimethyl fumarate) have been approved, and several other oral medications are being evaluated in extensive MS development programs. Because of frequent ocular involvement, ophthalmologists are often involved in the care of MS patients and therefore need to be aware of the current treatment regimens prescribed by neurologists, some of which can have significant ophthalmic adverse events. We update the current advancements in the treatment of MS and discuss the published clinical data on the efficacy and safety of the currently approved and emerging oral therapies in MS. SN - 1879-3304 UR - https://www.unboundmedicine.com/medline/citation/26703886/Currently_approved_and_emerging_oral_therapies_in_multiple_sclerosis:_An_update_for_the_ophthalmologist_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0039-6257(15)30048-5 DB - PRIME DP - Unbound Medicine ER -